Lieser M J, Barry M K, Rowland C, Ilstrup D M, Nagorney D M
Department of General Surgery, Mayo Clinic, Rochester, MN 55902, USA.
J Hepatobiliary Pancreat Surg. 1998;5(1):41-7. doi: 10.1007/pl00009949.
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignant primary tumor of the liver. It is, though, a rare tumor and little is known regarding its natural history, clinicopathologic characteristics, or the outcomes of surgical therapy. We reviewed the experience of 61 patients with ICC seen by the surgical service at the Mayo Clinic over a 31-year period. Patient demographic and clinical data were recorded, as were survival statistics. Pathologic data were also obtained and patients stratified according to the TNM classification. Twenty-eight patients were resected for cure. Overall, 45 patients died of ICC. Of the patients resected for cure, survival at 3 years was 60%. No pathologic condition was found to be associated with the development of ICC. Overall survival correlated with stage of the tumor. Among patients resected for cure, stage did not correlate with survival. Prognosis for patients with ICC remains poor; resection, though, appears to prolong survival.
肝内胆管癌（ICC）是肝脏第二常见的原发性恶性肿瘤。然而，它是一种罕见肿瘤，关于其自然病史、临床病理特征或手术治疗结果，人们知之甚少。我们回顾了梅奥诊所外科在31年期间诊治的61例肝内胆管癌患者的情况。记录了患者的人口统计学和临床数据以及生存统计数据。还获取了病理数据，并根据TNM分类对患者进行分层。28例患者接受了根治性切除。总体而言，45例患者死于肝内胆管癌。接受根治性切除的患者，3年生存率为60%。未发现有任何病理状况与肝内胆管癌的发生相关。总生存与肿瘤分期相关。在接受根治性切除的患者中，分期与生存无关。肝内胆管癌患者的预后仍然很差；不过，手术切除似乎能延长生存期。
